Evercore ISI analyst Cory Kasimov initiated coverage of Oric Pharmaceuticals (ORIC) with an Outperform rating and $25 price target The firm sees a “compelling” opportunity for the company in the “large” prostate cancer market. Oric’s lead asset ORIC-944 has the potential to bring a highly effective oral agent across multiple settings, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Promising Potential of Oric Pharmaceuticals’ ORIC-944 in Prostate Cancer Market Drives Buy Rating
- Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan
- Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
- Oric Pharmaceuticals price target raised to $16 from $12 at Citi
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications